Chair and Presenters Taofeek K. Owonikoko, MD, PhD, Anne Chiang, MD, PhD, FASCO, and Jared Weiss, MD, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/AAPA/IPCE activity titled “Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/426IDlG. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.
Effect of Time of Echo on 1H-magnetic Resonance Spectroscopy Imaging of Metab...submissionclinmedima
Similar to Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic (20)
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
1. SCLC Treatment Algorithm1-3,a
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/FUR40
a
This algorithm was created by Aakash Desai, MBBS, MPH, and used with his permission.
1. Paz-Ares L et al. ESMO Open. 2022;7:100408. 2. Paz-Ares L et al. ESMO 2021. Abstract LBA61. 3. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. Version 2.2024.
https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
CT abdomen/pelvis, PET/CT scan (if needed), MRI brain, PFTs,
bone marrow biopsy (select cases), mediastinal staging (stage I-IIA)
Stage and Workup
Is Cancer confined to one hemithorax and regional lymph nodes (can be treated with single radiation field)?
!"#"$%&'($)*%
?#*@*&#($2,'$+'(%+3(-+$,2$0"'%+*)($*-+(-+
Limited-Stage Disease
Eligible for treatment of curative intent
%4$%5("6%'($)*%
Extensive-Stage Disease
Stage III/IV disease; not eligible for treatment of curative intent
YES NO
STAGE I-IIA
STAGE IIB-IIIC
Pathologic
mediastinal
staging
Positive
Negative
Platinum-based
chemotherapy
+ concurrent RT
(PS 0-2)
or
± RT (PS 3-4 due
to SCLC)
JCOG 9104:
Concurrent RT vs
sequential RT
• mOS: 27.2
vs 19.7 mo
• HR: 0.70
Lobectomy + mediastinal LN
dissection or sampling
Platinum-based
chemotherapy
Platinum-based
chemotherapy
+
mediastinal RT
R0, N0
R0, N+
and/or
R1-2
Take into account PS, comorbidities, and age
Meta-analysis: PCI vs no PCI
RR of death HR: 0.84 (P = .01)
Prophylactic Cranial Irradiation in Patients Achieving Remission (ALL Stages)
PS ≤2 or ≥3 due to SCLC
PS ≥3 not due
to SCLC
Individualized
therapy in
consult with
palliative
medicine
1L: Chemo-immunotherapy
If ineligible for
immunotherapy,
use platinum-
based
chemotherapy
>6 mo CTFI?
Relapse
Yes No
2L: Chemotherapy
2L: Chemotherapy
Carboplatin + etoposide + atezolizumab
with maintenance atezolizumab
IMpower133: Chemo + atezo vs chemo
• mOS: 12.3 vs 10.3 mo
• HR: 0.76
Carboplatin or cisplatin + etoposide +
durvalumab with maintenance durvalumab
CASPIAN: Chemo + durva vs chemo
• mOS: 12.9 vs 10.5 mo
• HR: 0.71
Rechallenge with original
platinum-based
chemotherapy (preferred)
Lurbinectedin (recommended)
Phase 2 basket trial: Single arm
• ORR: 35.2%
• mDOR: 5.1 mo
For complete treatment
recommendations and
regimens, refer to the
NCCN guidelines
Lurbinectedin (preferred)
Phase 2 basket trial: Single arm
• ORR: 35.2%
• mDOR: 5.1 mo
Topotecan (preferred)
Trial: Topotecan vs CAV
• ORR: 23.3% vs 18.3%
Clinical trials (preferred)
For complete treatment
recommendations and
regimens, refer to the
NCCN guidelines
Clinical trials (preferred)
T1-2, N0, M0
T3-4, N0, M0
T1-4, N1-3, M0
?
2. Research Trends and Emerging
Therapies in SCLC
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/FUR40
1. Gay MG et al. Cancer Cell. 2021;39:346-360.
Clinical Studies Informing the Use of Current Therapy
Transcriptional Signatures,
Subtypes, and Therapeutic
Vulnerabilities1
Novel Therapeutic Approaches
on the Horizon
Selected Studies for Immunotherapy in LS-SCLC
Selected Studies for First- and Later-Line ES-SCLC
Bispecific T-Cell Engager (BiTE)
Antibody–Drug Conjugates (ADCs)
ADRIATIC
Phase 3 trial of durvalumab or durvalumab + tremelimumab as consolidation treatment in LS-SCLC
NRG/Alliance LU005
Phase 2/3 trial of atezolizumab ± cCRT in LS-SCLC
ASTRUM-005
Phase 3 trial of 1L serplulimab + chemo vs chemo
in ES-SCLC
KEYVIBE-008
Phase 3 trial of 1L vibostolimab + pembrolizumab
+ chemo vs atezolizumab + chemo in ES-SCLC
NCT04702880
Phase 2 trial of 1L BMS-986012 + nivolumab + chemo
in ES-SCLC
LAGOON
Confirmatory phase 3 trial of lurbinectedin in relapsed SCLC
IMforte
Phase 3 trial of lurbinectedin + atezolizumab as maintenance
therapy in ES-SCLC following 1L immunochemotherapy
LUPER
Phase 1/2 trial of lurbinectedin + pembrolizumab in relapsed SCLC
DeLLphi-300
Phase 1 trial of tarlatamab monotherapy or in combination with ICIs in SCLC
ORR: 23%, mPFS: 3.7 mo; mOS: 13.2 mo
DeLLphi-301
Phase 2 trial of tarlatamab in ≥3L SCLC
ORR: 40% for 10-mg group, 32% for 100-mg group
mPFS: 4.9 mo for 10-mg group, 3.9 mo for 100-mg group
NCT04145622
Phase 1/2 FIH trial of ifinatamab deruxtecan (B7-H3 targeting ADCs) in
solid tumor, including SCLC
NCT05280470
Phase 2 trial of ifinatamab deruxtecan in pre-treated ES-SCLC
IMMU-132-01
Phase 1/2 trial of sacituzumab govitecan (TROP2 targeting ADCs) in
epithelial cancer, including SCLC
Antibody Chemo
drug
+ =
Antibody–drug
conjugates
FDA
priority
review